“We are excited to offer full service testing for the state’s exploding adult-use market. The first two recreational cannabis dispensaries opened on November 20, 2018 and according to the CCC, sales exceeded $2 million in the first five days. Additional dispensaries are awaiting final license approval to enter this $1.2B cannabis market. We have already established relationships with a majority of the growers and producers across the Commonwealth and we look forward to serving them,” said Lori Glauser, COO of EVIO, in a media release. “As more consumers try cannabis including CBD products, it is vitally important that the product is safe, and the product labels are accurate.”
The provisional license permits EVIO Labs to complete the relocation to its new Framingham facility, reoptimize the equipment to support EVIO’s ISO accredited methods and complete preparations for final inspection.
The Oregon-based company is forecasting this process will be complete within the next 30 to 45 days.
The company has leased space on Speen Street.
EVIO Inc. is a leading provider of cannabis testing and scientific research for the regulated cannabis industry.
The company’s EVIO Labs division operates coast-to-coast providing state-mandated ancillary services to ensure the safety and quality of the nation’s cannabis supply.
The company’s EVIO Biosciences Division is dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the endocannabinoid system.